Additional Supporting Information may be found in the online version of this article.

STEM_537_sm_suppinfofigure1.tif5321KSupplementary figure 1. FACS controls. A/ Analysis of freshly sorted CD56+GFP− and CD56+GFP+ cells from a mixed population (50%/50%). B/ GFP analysis of cells sorted (CD56+GFP− or CD56+GFP+) and cloned (one cell by well in 96 well plates) using a FACS Aria cell sorter linked to an Automated Deposition Cell Unit. After 2 weeks of amplification, 30 clones were found to be fully GFP−, 40 clones were found to be GFP+ and no clones were found with a mixture of GFP+ and GFP− cells. Part of the total analysis is displayed under histogram or dot plot representation. C/ Example of compensation and isotype control assay for CD15−FITC and CD56−PE FACS analysis of cultivated muscle−derived cells.
STEM_537_sm_suppinfofigure2.tif741KSupplementary figure 2. A/ RT−PCR was performed to quantify the expression of various markers of adipogenesis or myogenesis from CD15+/−CD56+/− cells cultivated for 10 or 7 days in adipogenic or myogenic medium, respectively. UCP1 and CIDEA were amplified to investigate the presence of brown adipocytes. 18S rRNA and β-actin were amplified as controls. B/ RT−PCR analysis of CD34+CD15+CD56+, CD34+CD15−CD56+ and CD34−CD15−CD56+ sorted cells, freshly cultivated (passage 1) in proliferation medium, and prepared from b7 and b8 muscle samples. Whole muscle-derived cells were used as positive control. PAX7 and MYF5 were amplified as markers of the satellite cell lineage, and PRDM16 and MYF5 as markers of the muscle/brown adipocyte lineage. PW1 is a marker in mouse of both satellite cells and a subset of interstitial cells. 18S rRNA was amplified as control.
STEM_537_sm_suppinfofigure3.tif5474KSupplementary figure 3. Gallery of CD15−FITC (FL1−H) and CD56−PE (FL2−H) FACS profiles for freshly cultivated muscle-derived cells purified from healthy or pathological biopsies. Biopsies b1 to b8 correspond to biopsies described in Supplementary table 2. DM1 = type 1 myotonic dystrophy; FSH = facioscapulohumeral muscular dystrophy.
STEM_537_sm_suppinfotable1.tif538KSupporting Information Table 1
STEM_537_sm_suppinfotable2.tif256KSupporting Information Table 2

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.